Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials

Authors

Elizabeth Berry‐Kravis

Published

January 13, 2016

Abstract

In contrast to previous studies, targeting the mGluR pathway in fragile X syndrome patients did not improve behavior independent of FMR1 methylation.

Supporters

Support the authors with ResearchCoin

Journal

Science Translational Medicine

Topics

DOI

10.1126/scitranslmed.aab4109

Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials

Authors

Elizabeth Berry‐Kravis

Published

January 13, 2016

Abstract

In contrast to previous studies, targeting the mGluR pathway in fragile X syndrome patients did not improve behavior independent of FMR1 methylation.

Supporters

Support the authors with ResearchCoin

Journal

Science Translational Medicine

Topics

DOI

10.1126/scitranslmed.aab4109

Paper

Paper

Paper

Paper

Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials

Abstract

Supporters

Journal

Topics

DOI

Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials

Abstract

Supporters

Journal

Topics

DOI